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Abstract  
The β-epimer of methyl (1S,2R,4R)-N-benzoyl-2-formyl-7-azabicyclo[2.2.1]heptane-1-
carboxylate, (1S, 2S, 4R)-7, has been obtained by treatment of the exo-formyl derivative with 
triethylamine in methanol. The development of this epimerization procedure has further 
increased the already wide possibilities offered by our methodology and solves the problem of 
access to the endo derivatives that would result from the Diels–Alder reaction of Danishefsky’s 
diene and the C-4 unsaturated E-oxazolones, whose preparation frequently proves to be 
problematic. 
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Introduction 
 
The introduction of rigidity into bioactive peptides has proven to be a useful tool to study the 
conformational requirements for biological activity.1 Proline and analogues are well known for 
their ability to introduce conformational restrictions into bioactive peptides by inducing the 
formation of β-turns as well as influencing the protein folding.2 The replacement of proline with 
more constrained analogues provides additional information about receptor recognition and 
affinity. 
 Initial results showing the benefits of replacing proline with analogues containing a 7-
azabicyclo[2.2.1]heptane skeleton (2,5-ethanoproline),3 along with the increasing interest in 
structural studies of β-substituted prolines,4 encouraged us to intensify our synthetic efforts on 
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the development of a versatile methodology for the synthesis of enantiopure β-substituted proline 
analogues with the 7-azanorbornane skeleton – a special kind of amino acid in which the rigidity 
provided by the azabicyclic skeleton is combined with the presence of a β-substituent that 
mimics the α-amino acid side chain. 
 On the other hand, the discovery of epibatidine – an alkaloid with exceptional biological 
properties and possible clinical applications – by Daly and co-workers in 19925 has led to efforts 
to construct such ring systems.6 However, very few procedures have been described to date on 
the synthesis of enantiomerically pure proline analogues containing the azabicyclic ring,7 a fact 
that provided more than enough reason to justify our interest in these systems. 
 Our main objective in this study was the development of a versatile and efficient 
methodology for the synthesis of both enantiomers of a wide variety of azabicyclic prolines with 
a β-substituent in an exo disposition.7f-h,8 As part of our current research project devoted to 
determining the conformational preferences of constrained analogues of non-proteinogenic 
amino acids when incorporated into a peptide chain,9 we evaluated the structural consequences 
arising form the replacement of the proline residue in peptide models by these proline-α-amino 
acid chimeras.3c,3d  
 The promising results reported in this recent study focused our interest on extending the 
developed methodology to the synthesis of a new series of β-endo-substituted azabicyclic 
prolines as a source of surrogates to be incorporated into model peptides whose structural and 
biological study would shed light on the nature of the effects induced by this type of 
conformational restriction and the influence of the absolute configurations of the stereogenic 
centers.  
 
 
Results and Discussion 
 
Recently, we developed a new route for the synthesis of a wide variety of enantiomerically pure 
exo-2-substituted 7-azabicyclo[2.2.1]heptane-1-carboxylic acid derivatives. This approach 
allowed a racemic and an asymmetric version to be applied in a complementary manner. Our 
overall strategy is based on the preparation of valuable azabicyclic intermediates through a key 
step that involves cyclization of cyclohexylamine derivatives obtained from the transformation 
of the cycloadducts provided by the Diels–Alder reaction of C-4 unsaturated 5(4H)-oxazolones 
and Danishefsky’s diene.  
 The cycloaddition of Danishefsky’s diene and (Z)-2-phenyl-4-benzylidene-5(4H)-
oxazolone (Z)-1 or (Z)-2-phenyl-4-(thien-2-ylmethylene)-5(4H)-oxazolone (Z)-2, followed by 
manipulation of the resulting adducts, has allowed the multigram-scale synthesis of a racemic 
mixture of methyl N-benzoyl-2-exo-(phenyl)-7-azabicyclo[2.2.1]heptane-1-carboxylate (rac-exo-
3)8a and methyl N-benzoyl-2-exo-(thien-2-yl)-7-azabicyclo[2.2.1]heptane-1-carboxylate (rac-
exo-4),8b respectively (Scheme 1). Once the synthesis of the racemic compounds had been 
achieved, we undertook the isolation of the enantiopure compounds on a preparative scale by 
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HPLC resolution using a non-commercial chiral stationary phase, which provided each 
enantiomer separately with high efficiency.  
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Scheme 1 
 
 The extension of our methodology to an asymmetric version starting from the chiral C-4 
unsaturated oxazolone 5, which is derived from (R)-glyceraldehyde, allowed the stereoselective 
synthesis of methyl (1S,2R,4R)-N-benzoyl-2-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]-7-
azabicyclo[2.2.1]heptane-1-carboxylate (6), another enantiopure key intermediate on a 40 gram 
scale (Scheme 2).7f-h 
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 As described previously, compounds 3, 4 and 6 in enantiomerically pure form have proven 
to be very useful intermediates for the synthesis of a wide variety of β-substituted azabicyclic 
prolines in an exo disposition due to the transformation into other synthetically flexible functions 
such as formyl or hydroxymethyl groups (Scheme 3).8,10 As we have demonstrated in previous 
studies, this stereocontrolled functionalization offered extensive choice for subsequent 
transformations on the amino acid side chain. Olefination reactions and SN2 displacements at the 
γ-position have generated a wide range of possibilities for the preparation of a very special type 
of amino acids in which the rigidity provided by the azabicyclic skeleton is combined with the 
presence of a β-substituent, which mimics the α-amino acid side chain (Scheme 3).10,11 
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Scheme 3 
 
 Taking into account the efficacy of the established synthetic method, our next aim was to 
extend the approach to the synthesis of the corresponding enantiomerically pure endo 
stereoisomers of β-substituted prolines that incorporate the 7-azanorbornane core. In principle, 
access to these compounds would involve the use of the corresponding C-4 unsaturated 5(4H)-
oxazolone as the starting material, but according to our previous experience the synthesis of the 
dienophile is, to say the least, problematic and under classical Diels–Alder conditions 
isomerization to the most stable Z-isomer occurs, giving rise to a complex mixture of 
cycloadducts.12 
 During the course of our previous studies, we found that intermediate (1S,2R,4R)-7 proved 
to be exceedingly susceptible to base-induced epimerization. In fact, oxidation of alcohol 
(1S,2R,4R)-8 under Swern conditions with oxalyl chloride, Et3N and DMSO in dichloromethane 
provided a 70:30 mixture of the β-formyl derivative (1S,2R,4R)-7 and its C-2 epimer in 97% 
combined yield.8a On the other hand, in the study of the Wittig reaction of (1S,2R,4R)-7 some of 
the conditions led to a mixture of C-2 epimeric products due to partial epimerization at C-2.10 
The ease with which this intermediate undergoes epimerization at the stereocenter adjacent to the 
aldehyde group prompted us to explore its potential utility to achieve our objective. 
 To the best of our knowledge, the literature reports only epimerization procedures in a 7-
azabicyclo[2.2.1]heptane skeleton applied to the synthesis of the thermodynamically more stable 
exo-epibatidine derivatives.13 The notoriously problematic epimerization of endo-epibatidine to 
the corresponding exo-isomer using potassium tert-butoxide in refluxing tert-butyl alcohol was 
finally improved by simply using microwave irradiation in the presence of potassium tert-
butoxide in tert-butanol.13d However, attempts to bring about epimerization of other epibatidine 
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analogues using standard protocols (K2CO3/MeOH, NaH/THF, p-TsOH/toluene, tBuOK/tBuOH) 
failed and in this case a silica gel-catalyzed epimerization was found to be the best procedure.13g  
In accordance with these reports and taking into account the highly favorable exo-epimerization 
under thermodynamic conditions, we decided to evaluate the opposite epimerization process at 
C-2 of the exo-formyl derivative (1S,2R,4R)-7 at low temperatures in an effort to provide the 
kinetically controlled product. 
 In this context, we started the epimerization study using NaH as a base in dry THF and the 
reaction was performed at –78 ºC over a range of reaction times. However, these conditions 
afforded only the starting material without the presence of any epimerization product. Therefore, 
we decided to increase the reaction temperature and when the reaction was carried out at –20 ºC 
a 39/61 mixture of the endo and exo stereoisomers was obtained. The reaction mixtures resulting 
from the evaporation of the solvent were analysed by 1H NMR spectroscopy, and the 
determination of the endo/exo ratio was carried out by integration of the signals of the aldehyde 
proton (10.01 and 9.89 ppm for the endo and exo-isomers, respectively) and the methyl 
carboxylate (3.87 and 3.80 ppm for the endo and exo-isomers, respectively) in the 1H NMR 
spectrum of the crude material. In order to improve the epimerization ratio, the reaction mixture 
was allowed to warm up to room temperature after addition of the base at –20 ºC and this led to 
an increase in the proportion of the endo epimer of aldehyde 7 to a 55/45 ratio. Unfortunately, all 
attempts to improve the epimerization process by increasing the reaction time to room 
temperature failed, resulting only in the decomposition of the starting material. Similar results 
were obtained when aldehyde (1S,2R,4R)-7 was allowed to react with LDA in dry THF, but in 
this case the best rate of epimerization was reached at –20 ºC (endo/exo: 45/55) and an increase 
in the reaction temperature proved unsuccessful for any reaction time. 
 All our epimerization efforts proved unsuccessful and we therefore planned to study the 
epimerization process using the reported procedures. Initially, we tried potassium tert-butoxide 
and the reaction of (1S,2R,4R)-7 with this base in dry tert-butyl alcohol at room temperature 
resulted in the decomposition of the starting material after only 30 minutes of reaction. In 
contrast, the use of potassium carbonate in THF/water under reflux afforded a 55/45 mixture of 
the endo/exo epimers but in very low overall yield due to saponification of the methyl 
carboxylate substituent at C-1. 
 Finally, due to the lack of satisfactory results and the known problems associated with 
epimerization when an epimerization-prone aldehyde is obtained under Swern conditions using 
Et3N as base,14 we decided to explore the behavior of this base in the epimerization study. 
Treatment of derivative (1S,2R,4R)-7 with Et3N using methanol as a solvent at room temperature 
for 4 days gave a 70/30 mixture of the endo/exo isomers in the crude reaction mixture, as 
determined by integration of the 1H NMR signals. These satisfactory results encouraged us to 
investigate this reaction under several sets of reaction conditions. However, the ratio did not 
change when the reaction time was extended (more than 30 days). We therefore decided to 
explore the reaction at 40 ºC, but the ratio of epimerization was the same as before and the 1H 
NMR spectrum of the crude reaction mixture contained other signals (which were not 
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characterized). Finally, reaction of the aldehyde with a large excess of Et3N (using this reagent as 
a solvent) did not lead to a better epimerization ratio.  
 On the basis of these results, we decided to attempt the isolation of the two epimers. The 
chromatographic separation of the resulting mixtures (70/30) on silica gel using hexane/ethyl 
acetate as eluent in a gradient form (6:4 to 1:1) furnished the major stereoisomer (1S,2S,4R)-7 in 
enantiomerically pure form and allowed the recovery of the starting material (1S,2R,4R)-7 
(Scheme 4). 
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 In this way we have established an efficient synthetic method for the preparation of the 
desired aldehyde (1S,2S,4R)-7 in enantiomerically pure form. 
 Once the epimerization conditions had been optimized, we decided to begin a program 
aimed at preparing the series of endo-derivatives by using stereo controlled procedures and with 
the new intermediate (1S,2S,4R)-7 as the starting material.  
 Firstly, as an example of the versatility of the methodology, we studied the transformation 
of aldehyde (1S,2S,4R)-7 into another functionalized intermediate – alcohol (1S,2S,4R)-8. As 
reported for the exo series,11 the reduction was achieved by treatment with NaBH4 in a 
methanol/water mixture to provide the primary alcohol in almost quantitative yield (97%) 
(Scheme 5). 
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 The rigorous proof of the assignment of the endo stereochemistry at C-2 was provided by 
single-crystal X-ray analysis of compound (1S,2S,4R)-8, as shown in Figure 1. These data 
unambiguously demonstrate the endo configuration at the β-position of the azabicyclic skeleton.  
 
 
 
Figure 1. ORTEP drawing of compound (1S,2S,4R)-8. Non-hydrogen atoms are represented by 
ellipsoids corresponding to 25% probability. The hydroxylic and C-2 hydrogens are represented 
by spheres of arbitrary size, the rest of the hydrogen atoms have been omitted for clarity. 
 
 Given the ready availability of epimerized alcohol (1S,2S,4R)-8 and in order to compare its 
reactivity with that of the β-epimer described in some of our previous papers, we decided to 
carry out a study of SN2 displacements at the γ-position.  
 The introduction of bromide, the leaving group that showed the best results in our previous 
work, was carried out by treatment of (1S,2S,4R)-8 with N-bromosuccinimide and 
triphenylphosphine, which provided bromo derivative (1S,2S,4R)-9 in 80% yield (Scheme 6). 
 Finally, the behavior of bromide (1S,2S,4R)-9 as a leaving group was studied by 
investigating displacement by hydride. The reaction of (1S,2S,4R)-9 with sodium borohydride in 
HMPA under reflux afforded the corresponding derivative (1S,2S,4R)-10 in excellent yield. 
 
NPh
O
MeOOC
Br
NPh
O
MeOOC CH3
(1S,2S,4R)-9 (1S,2S,4R)-10
N-bromosuccinimide,
PPh3, THF, 40 ºC
80%
NaBH4,
HMPA, 70 ºC
90%
NPh
O
MeOOC
(1S,2S,4R)-8
OH
 
 
Scheme 6 
 
Issue in Honor of Prof. Joan Bosch                                                                              ARKIVOC 2007 (iv) 157-169 
ISSN 1424-6376                                                       Page 164                                                       ©ARKAT USA, Inc. 
 In a similar manner, other transformations aimed at completing the family of endo-
derivatives are currently being studied in our laboratory and will be published in due course.  
 
 
Conclusions 
 
The work described here has extended our previously reported methodology to the synthesis of 
enantiomerically pure endo stereoisomers of β-substituted prolines that incorporate the 7-
azanorbornane skeleton. 
 To achieve this target, we studied the epimerization at C-2 of aldehyde (1S,2R,4R)-7 and 
the subsequent transformation of the β-epimer (1S,2S,4R)-7 into methyl (1S,2S,4R)-N-benzoyl-2-
methyl-7-azabicyclo[2.2.1]heptane-1-carboxylate (1S,2S,4R)-10. The excellent results obtained 
in this preliminary study offer a wide range of possibilities and clearly demonstrate the 
unquestionable potential of this methodology.  
 
 
Experimental Section 
 
General Procedures. Melting points were determined using a Büchi SMP-20 apparatus. IR 
spectra were registered on a Mattson Genesis FTIR spectrophotometer; νmax is given for the main 
absorption bands. 1H and 13C NMR spectra were recorded on a Bruker ARX-300 spectrometer at 
room temperature, using the residual solvent signal as the internal standard; chemical shifts (δ) 
are quoted in ppm, and coupling constants (J) are measured in Hertz. Optical rotations were 
measured in a cell with a 10 cm pathlength at 25 ºC using a JASCO P-1020 polarimeter. The ESI 
mass spectra were recorded on a Bruker MicroTof-Q spectrometer. TLC was performed on 
Polygram® sil G/UV254 precoated silica gel polyester plates and products were visualised under 
UV light (254 nm), anisaldehyde or phosphomolybdic acid developers. Column chromatography 
was performed using silica gel (Kieselgel 60). Methyl (1S,2R,4R)-N-benzoyl-2-formyl-7-
azabicyclo[2.2.1]heptane-1-carboxylate (7) was obtained according to the reported procedure.10 
X-ray diffraction. The X-ray diffraction data were collected at room temperature on an Oxford 
Diffraction Xcalibur O diffractometer with a Sapphire CCD detector, using graphite-
monochromated Mo-Kα radiation (λ = 0.71073 Å). The structure was solved by direct methods 
using SHELXS 9715 and refinement was performed using SHELXL 9716 by the full-matrix least-
squares technique with anisotropic thermal factors for heavy atoms. 
Colorless single crystals of (1S,2S,4R)-8 were obtained by slow evaporation from an ethyl 
acetate/ether solution. Reflections were measured in the ω/2θ scan mode in the θ range 2.77–
26.00º. Hydrogen atoms were located by calculation (with the exception of the hydroxylic 
proton, which was found on the E-map) and affected by an isotropic thermal factor fixed to 1.2 
times the Ueq value of the carrier atom (1.5 for the methyl protons). Crystallographic data: 
tetragonal, P41212; a = 10.3837(1) Å; b = 10.3837(1) Å, c = 26.8853(7) Å; Z = 8; d (calcd.) = 
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1.326 g cm–3; reflections collected/independent: 36330/2854 [R(int) = 0.0792]; data/parameters: 
2854/191; final R indices [I>2σ(I)]: R1 = 0.0287 wR2 = 0.0458; final R indices (all data): R1 = 
0.0710, wR2 = 0.0491. 
Crystallographic data (excluding structure factors) for the structure of compound (1S,2S,4R)-8 
have been deposited with the Cambridge Crystallographic Data Centre as supplementary 
publication number CCDC 616701. Copies of the data can be obtained, free of charge, via 
http://www.ccdc.cam.uk/conts/retrieving.html or on application to CCDC, 12 Union Road, 
Cambridge CB2 1EZ, UK [fax: +44(0)-1223-336033 or e-mail: deposit@ccdc.cam.ac.uk]. 
Methyl (1S,2S,4R)-N-benzoyl-2-formyl-7-azabicyclo[2.2.1]heptane-1-carboxylate (7). To a 
solution of methyl (1S,2R,4R)-N-benzoyl-2-formyl-7-azabicyclo[2.2.1]heptane-1-carboxylate (7) 
(200 mg, 0.70 mmol) in methanol (5 mL) was added triethylamine (0.15 mL, 1.05 mmol) and the 
reaction mixture was stirred at room temperature for 4 d. The solvent was evaporated under 
vacuum and the 1H NMR spectrum of the crude residue revealed a 70/30 mixture of endo/exo 
formyl derivative. The chromatographic separation of the resulting mixture using hexane/ethyl 
acetate as eluent in a gradient form (6:4 to 1:1) supplied the major stereoisomer (1S,2S,4R)-7 in 
66% yield (133 mg, 0.46 mmol) as a colorless oil and allowed recovery of the starting material 
(1S,2R,4R)-7 (57 mg) [the spectroscopic data for epimer (1S,2R,4R)-7 are identical to those 
described in the literature].7f [α]D = +146.8 (c 0.5 CHCl3); IR (neat) ν (cm–1): 1741, 1651, 1616, 
1575. 
1
H NMR (CDCl3) δ (ppm): 10.01 (s, 1H), 7.69–7.67 (m, 2H), 7.53–7.48 (m, 1H), 7.43–
7.40 (m, 2H), 4.29 (dd, 1H, J = 4.9 Hz, J = 4.9 Hz), 3.87 (s, 3H), 3.79 (ddd, 1H, J = 11.4 Hz, J = 
4.4 Hz, J = 2.8 Hz), 2.30–2.21 (m, 1H), 2.16–2.07 (m, 2H), 1.85–1.70 (m, 2H), 1.59 (ddd, 1H, J 
= 11.9 Hz, J = 9.2 Hz, J = 4.6 Hz). 
13
C NMR (CDCl3) δ (ppm): 201.0, 172.6, 170.6, 133.8, 
132.0, 128.7, 128.5, 69.0, 62.8, 53.5, 52.9, 31.3, 30.0, 29.3. HRMS (ESI) C16H17NO4Na [M + 
Na]+ calcd. 310.104979, found 310.105584. 
Methyl (1S,2S,4R)-N-benzoyl-2-hydroxymethyl-7-azabicyclo[2.2.1]heptane-1-carboxylate 
(8). To a solution of methyl (1S,2S,4R)-N-benzoyl-2-formyl-7-azabicyclo[2.2.1]heptane-1- 
carboxylate (7) (100 mg, 0.35 mmol) in methanol (6 mL) and water (1 mL) at 0 ºC was added 
NaBH4 (6.8 mg, 0.17 mmol) and the mixture was stirred for 1 h at this temperature. The reaction 
mixture was neutralised by addition of an aqueous solution of 0.5 M hydrochloric acid and the 
methanol was evaporated under vacuum. Water (25 mL) was added and the mixture extracted 
with dichloromethane (3 × 25 mL). The combined organic layers were dried over anhydrous 
magnesium sulfate, filtered and evaporated under vacuum. The residue obtained was purified by 
flash chromatography on silica gel using ether/ethanol (9:1) as eluent to afford the alcohol 
(1S,2S,4R)-8 (98 mg, 0.34 mmol) as a white solid in 97% yield. Mp = 102–103 °C; [α]D = +67.4 
(c 0.5 CHCl3); IR (KBr) ν (cm–1): 3453, 1739, 1626, 1573. 1H NMR (CDCl3) δ (ppm): 7.62–7.60 
(m, 2H), 7.45–7.41 (m, 1H), 7.36–7.33 (m, 2H), 4.20 (dd, 1H, J = 5.0 Hz, J = 5.0 Hz), 3.82–3.78 
(m, 1H), 3.80 (s, 3H), 3.60 (dd, 1H, J = 10.1 Hz, J = 10.1 Hz), 3.11 (br s, 1H), 3.04–2.95 (m, 
1H), 2.26–2.18 (m, 1H), 2.17–2.11 (m, 1H), 2.08–1.99 (m, 1H), 1.98–1.90 (m, 1H), 1.49 (ddd, 
1H, J = 12.2 Hz, J = 9.0 Hz, J = 5.1 Hz), 1.01 (dd, 1H, J = 12.2 Hz, J = 5.1 Hz). 
13
C NMR 
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(CDCl3) δ (ppm): 173.0, 172.1, 134.3, 131.6, 128.6, 128.4, 69.9, 63.2, 61.7, 52.8, 43.8, 34.9, 
30.9, 26.2. HRMS (ESI) C16H19NO4Na [M + Na]+ calcd. 312.120629, found 312.121756. 
Methyl (1S,2S,4R)-N-benzoyl-2-bromomethyl-7-azabicyclo[2.2.1]heptane-1-carboxylate (9). 
N-Bromosuccinimide (124.6 mg, 0.70 mmol) and triphenylphosphine (183.4 mg, 0.70 mmol) 
were added to a solution of methyl (1S,2S,4R)-N-benzoyl-2-hydroxymethyl-7-
azabicyclo[2.2.1]heptane-1-carboxylate (8) (100 mg, 0.35 mmol) in dry THF (5 mL) under an 
argon atmosphere and the resulting mixture was stirred at 40 ºC for 12 h. The solvent was 
removed and the resulting suspension was poured into water (25 mL) and extracted with 
dichloromethane (3 × 25 mL). The combined organic layers were dried with anhydrous 
magnesium sulfate, filtered and the solvent was removed under vacuum. Purification of the crude 
mixture by silica gel column chromatography eluting with a 7:3 mixture of hexane/ethyl acetate 
gave the bromide (1S,2S,4R)-9 as a white solid in 80% yield (11.5 mg, 0.28 mmol). Mp = 177–
178 °C; [α]D = +19.0 (c 0.5 CHCl3); IR (KBr) ν (cm–1): 1739, 1635. 1H NMR (CDCl3) δ (ppm): 
7.68–7.65 (m, 2H), 7.51–7.46 (m, 1H), 7.42–7.38 (m, 2H), 4.25 (dd, 1H, J = 5.0 Hz, J = 5.0 Hz), 
3.82 (s, 3H), 3.64 (dd, 1H, J = 9.8 Hz, J = 5.4 Hz), 3.34 (dd, 1H, J = 9.9 Hz, J = 9.9 Hz), 3.22–
3.13 (m, 1H), 2.55–2.38 (m, 2H), 2.03 (ddd, 1H, J = 13.2 Hz, J = 9.0 Hz, J = 4.3 Hz), 1.98–1.89 
(m, 1H), 1.54 (ddd, 1H, J = 12.3 Hz, J = 9.0 Hz, J = 4.9 Hz), 1.28 (dd, 1H, J = 12.5 Hz, J = 5.1 
Hz). 
13
C NMR (CDCl3) δ (ppm): 172.0, 170.5, 134.1, 131.7, 128.6, 128.4, 70.1, 62.0, 52.6, 45.6, 
37.7, 32.9, 30.7, 25.3. HRMS (ESI) C16H18BrNO3Na [M + Na]+ calcd. 374.036227, found 
374.037391. 
Methyl (1S,2S,4R)-N-benzoyl-2-methyl-7-azabicyclo[2.2.1]heptane-1-carboxylate (10). A 
solution of methyl (1S,2S,4R)-N-benzoyl-2-bromomethyl-7-azabicyclo[2.2.1]heptane-1-
carboxylate (9) (100 mg, 0.28 mmol) and NaBH4 (31.8 mg, 0.84 mmol) in HMPA (4 mL) was 
heated at 70 ºC for 12 h. The solution was allowed to cool down to room temperature and the 
resulting mixture was diluted with water (20 mL). The mixture was extracted with 
dichloromethane (3 × 10 mL). The combined organic layers were washed with water (10 ml), 
dried over anhydrous magnesium sulfate, filtered and the solvent was removed under vacuum. 
Finally, the residue was purified by chromatography using 9:1 dichloromethane/ethyl acetate as 
eluent. Compound (1S,2S,4R)-10 was isolated as a white solid in 90% yield (68.3 mg, 0.25 
mmol). Mp = 113–114 °C; [α]D = –6.9 (c 0.35 CHCl3); IR (KBr) ν (cm–1): 1730, 1638. 1H NMR 
(CDCl3) δ (ppm): 7.66–7.64 (m, 2H), 7.48–7.44 (m, 1H), 7.40–7.36 (m, 2H), 4.17 (dd, 1H, J = 
5.1 Hz, J = 5.1 Hz), 3.79 (s, 3H), 2.79–2.69 (m, 1H), 2.34–2.18 (m, 2H), 2.10 (ddd, 1H, J = 13.1 
Hz, J = 9.0 Hz, J = 4.5 Hz), 1.80–1.72 (m, 1H), 1.47 (ddd, 1H, J = 12.2 Hz, J = 9.0 Hz, J = 4.8 
Hz), 1.09 (d, 3H, J = 7.0 Hz), 0.98 (dd, 1H, J = 11.9 Hz, J = 5.2 Hz). 
13
C NMR (CDCl3) δ (ppm): 
172.1, 171.3, 134.5, 131.4, 128.6, 128.3, 70.8, 62.6, 52.3, 38.5, 38.3, 31.2, 24.0, 15.5. HRMS 
(ESI) C16H19NO3Na [M + Na]+ calcd. 296.125715, found 296.126712. 
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